REG - GSK PLC - Director/PDMR Shareholding
11/02/2026 15:30
For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20260211:nRSK6429Sa&default-theme=true
RNS Number : 6429S GSK PLC 11 February 2026
GSK plc (the 'Company')
Vesting of Conditional Share Awards under the Share Value Plan and Sale of
Ordinary Shares and American Depositary Shares
This notification sets out the vesting details for Persons Discharging
Managerial Responsibilities ('PDMRs') and their Persons Closely Associated
('PCAs') of conditional awards over Ordinary Shares and American Depositary
Shares ('ADS') made in 2023 under the GSK Share Value Plan and the subsequent
sale of Ordinary Shares and ADS to meet tax liabilities. The awards, which
were conditional on continued employment with the GSK group, vested on 9
February 2026.
Transaction notification
1. Details of PDMR/person closely associated with them ('PCA')
a) Name Lynn Baxter
b) Position/status President, Europe
c) Initial notification/ Initial notification
amendment
2. Details of the issuer, emission allowance market participant, auction
platform, auctioneer or auction monitor
a) Name GSK plc
b) LEI 5493000HZTVUYLO1D793
3. Details of the transaction(s): section to be repeated for (i) each type of
instrument; (ii) each type of transaction; (iii) each date; and (iv) each
place where transaction(s) has been conducted
a) Description of the financial instrument Ordinary shares of 31 ¼ pence each ('Ordinary Shares')
ISIN: GB00BN7SWP63
b) Nature of the transaction The vesting of Ordinary Shares awarded in 2023 under the Company's Share Value
Plan
c) Price(s) and volume(s) Price(s) Volume(s)
£0.00 10,050
d) Aggregated information N/A (single transaction)
Aggregated volume Price
e) Date of the transaction 2026-02-09
f) Place of the transaction N/A
1. Details of PDMR/person closely associated with them ('PCA')
a) Name Lynn Baxter
b) Position/status President, Europe
c) Initial notification/ Initial notification
amendment
2. Details of the issuer, emission allowance market participant, auction
platform, auctioneer or auction monitor
a) Name GSK plc
b) LEI 5493000HZTVUYLO1D793
3. Details of the transaction(s): section to be repeated for (i) each type of
instrument; (ii) each type of transaction; (iii) each date; and (iv) each
place where transaction(s) has been conducted
a) Description of the financial instrument Ordinary shares of 31 ¼ pence each ('Ordinary Shares')
ISIN: GB00BN7SWP63
b) Nature of the transaction The sale of Ordinary Shares to meet tax liabilities on the vesting of awards
granted in 2023 under the Company's Share Value Plan
c) Price(s) and volume(s) Price(s) Volume(s)
£21.9082 4,084
d) Aggregated information N/A (single transaction)
Aggregated volume Price
e) Date of the transaction 2026-02-09
f) Place of the transaction London Stock Exchange (XLON)
1. Details of PDMR/person closely associated with them ('PCA')
a) Name Mike Crichton
b) Position/status President, International
c) Initial notification/ Initial notification
amendment
2. Details of the issuer, emission allowance market participant, auction
platform, auctioneer or auction monitor
a) Name GSK plc
b) LEI 5493000HZTVUYLO1D793
3. Details of the transaction(s): section to be repeated for (i) each type of
instrument; (ii) each type of transaction; (iii) each date; and (iv) each
place where transaction(s) has been conducted
a) Description of the financial instrument Ordinary shares of 31 ¼ pence each ('Ordinary Shares')
ISIN: GB00BN7SWP63
b) Nature of the transaction The vesting of Ordinary Shares awarded in 2023 under the Company's Share Value
Plan
c) Price(s) and volume(s) Price(s) Volume(s)
£0.00 10,050
d) Aggregated information N/A (single transaction)
Aggregated volume Price
e) Date of the transaction 2026-02-09
f) Place of the transaction N/A
1. Details of PDMR/person closely associated with them ('PCA')
a) Name Mike Crichton
b) Position/status President, International
c) Initial notification/ Initial notification
amendment
2. Details of the issuer, emission allowance market participant, auction
platform, auctioneer or auction monitor
a) Name GSK plc
b) LEI 5493000HZTVUYLO1D793
3. Details of the transaction(s): section to be repeated for (i) each type of
instrument; (ii) each type of transaction; (iii) each date; and (iv) each
place where transaction(s) has been conducted
a) Description of the financial instrument Ordinary shares of 31 ¼ pence each ('Ordinary Shares')
ISIN: GB00BN7SWP63
b) Nature of the transaction The sale of Ordinary Shares to meet tax liabilities on the vesting of awards
granted in 2023 under the Company's Share Value Plan
c) Price(s) and volume(s) Price(s) Volume(s)
£21.9082 3,920
d) Aggregated information N/A (single transaction)
Aggregated volume Price
e) Date of the transaction 2026-02-09
f) Place of the transaction London Stock Exchange (XLON)
1. Details of PDMR/person closely associated with them ('PCA')
a) Name Maya Martinez-Davis
b) Position/status President, US
c) Initial notification/ Initial notification
amendment
2. Details of the issuer, emission allowance market participant, auction
platform, auctioneer or auction monitor
a) Name GSK plc
b) LEI 5493000HZTVUYLO1D793
3. Details of the transaction(s): section to be repeated for (i) each type of
instrument; (ii) each type of transaction; (iii) each date; and (iv) each
place where transaction(s) has been conducted
a) Description of the financial instrument American Depositary Shares ('ADS')
ISIN: US37733W2044
b) Nature of the transaction The vesting of ADS awarded in 2023 under the Company's Share Value Plan
c) Price(s) and volume(s) Price(s) Volume(s)
$0.00 10,658
d) Aggregated information N/A (single transaction)
Aggregated volume Price
e) Date of the transaction 2026-02-09
f) Place of the transaction N/A
1. Details of PDMR/person closely associated with them ('PCA')
a) Name Maya Martinez-Davis
b) Position/status President, US
c) Initial notification/ Initial notification
amendment
2. Details of the issuer, emission allowance market participant, auction
platform, auctioneer or auction monitor
a) Name GSK plc
b) LEI 5493000HZTVUYLO1D793
3. Details of the transaction(s): section to be repeated for (i) each type of
instrument; (ii) each type of transaction; (iii) each date; and (iv) each
place where transaction(s) has been conducted
a) Description of the financial instrument American Depositary Shares ('ADS')
ISIN: US37733W2044
b) Nature of the transaction The sale of ADS to meet tax liabilities on the vesting of awards granted in
2023 under the Company's Share Value Plan
c) Price(s) and volume(s) Price(s) Volume(s)
$59.0729 2,789
d) Aggregated information N/A (single transaction)
Aggregated volume Price
e) Date of the transaction 2026-02-09
f) Place of the transaction New York Stock Exchange (XNYS)
1. Details of PDMR/person closely associated with them ('PCA')
a) Name Nina Mojas
b) Position/status President, Global Product Strategy
c) Initial notification/ Initial notification
amendment
2. Details of the issuer, emission allowance market participant, auction
platform, auctioneer or auction monitor
a) Name GSK plc
b) LEI 5493000HZTVUYLO1D793
3. Details of the transaction(s): section to be repeated for (i) each type of
instrument; (ii) each type of transaction; (iii) each date; and (iv) each
place where transaction(s) has been conducted
a) Description of the financial instrument Ordinary shares of 31 ¼ pence each ('Ordinary Shares')
ISIN: GB00BN7SWP63
b) Nature of the transaction The vesting of Ordinary Shares awarded in 2023 under the Company's Share Value
Plan
c) Price(s) and volume(s) Price(s) Volume(s)
£0.00 23,120
d) Aggregated information N/A (single transaction)
Aggregated volume Price
e) Date of the transaction 2026-02-09
f) Place of the transaction N/A
1. Details of PDMR/person closely associated with them ('PCA')
a) Name Nina Mojas
b) Position/status President, Global Product Strategy
c) Initial notification/ Initial notification
amendment
2. Details of the issuer, emission allowance market participant, auction
platform, auctioneer or auction monitor
a) Name GSK plc
b) LEI 5493000HZTVUYLO1D793
3. Details of the transaction(s): section to be repeated for (i) each type of
instrument; (ii) each type of transaction; (iii) each date; and (iv) each
place where transaction(s) has been conducted
a) Description of the financial instrument Ordinary shares of 31 ¼ pence each ('Ordinary Shares')
ISIN: GB00BN7SWP63
b) Nature of the transaction The sale of Ordinary Shares to meet tax liabilities on the vesting of awards
granted in 2023 under the Company's Share Value Plan
c) Price(s) and volume(s) Price(s) Volume(s)
£21.9082 6,104
d) Aggregated information N/A (single transaction)
Aggregated volume Price
e) Date of the transaction 2026-02-09
f) Place of the transaction London Stock Exchange (XLON)
1. Details of PDMR/person closely associated with them ('PCA')
a) Name Victoria Whyte
b) Position/status SVP & Company Secretary
c) Initial notification/ Initial notification
amendment
2. Details of the issuer, emission allowance market participant, auction
platform, auctioneer or auction monitor
a) Name GSK plc
b) LEI 5493000HZTVUYLO1D793
3. Details of the transaction(s): section to be repeated for (i) each type of
instrument; (ii) each type of transaction; (iii) each date; and (iv) each
place where transaction(s) has been conducted
a) Description of the financial instrument Ordinary shares of 31 ¼ pence each ('Ordinary Shares')
ISIN: GB00BN7SWP63
b) Nature of the transaction The vesting of Ordinary Shares awarded in 2023 under the Company's Share Value
Plan
c) Price(s) and volume(s) Price(s) Volume(s)
£0.00 10,050
d) Aggregated information N/A (single transaction)
Aggregated volume Price
e) Date of the transaction 2026-02-09
f) Place of the transaction N/A
1. Details of PDMR/person closely associated with them ('PCA')
a) Name Victoria Whyte
b) Position/status SVP & Company Secretary
c) Initial notification/ Initial notification
amendment
2. Details of the issuer, emission allowance market participant, auction
platform, auctioneer or auction monitor
a) Name GSK plc
b) LEI 5493000HZTVUYLO1D793
3. Details of the transaction(s): section to be repeated for (i) each type of
instrument; (ii) each type of transaction; (iii) each date; and (iv) each
place where transaction(s) has been conducted
a) Description of the financial instrument Ordinary shares of 31 ¼ pence each ('Ordinary Shares')
ISIN: GB00BN7SWP63
b) Nature of the transaction The sale of Ordinary Shares to meet tax liabilities on the vesting of awards
granted in 2023 under the Company's Share Value Plan
c) Price(s) and volume(s) Price(s) Volume(s)
£21.9082 4,724
d) Aggregated information N/A (single transaction)
Aggregated volume Price
e) Date of the transaction 2026-02-09
f) Place of the transaction London Stock Exchange (XLON)
1. Details of PDMR/person closely associated with them ('PCA')
a) Name Neil Falkingham
b) Position/status PCA of Lynn Baxter (President, Europe)
c) Initial notification/ Initial notification
amendment
2. Details of the issuer, emission allowance market participant, auction
platform, auctioneer or auction monitor
a) Name GSK plc
b) LEI 5493000HZTVUYLO1D793
3. Details of the transaction(s): section to be repeated for (i) each type of
instrument; (ii) each type of transaction; (iii) each date; and (iv) each
place where transaction(s) has been conducted
a) Description of the financial instrument Ordinary shares of 31 ¼ pence each ('Ordinary Shares')
ISIN: GB00BN7SWP63
b) Nature of the transaction The vesting of Ordinary Shares awarded in 2023 under the Company's Share Value
Plan
c) Price(s) and volume(s) Price(s) Volume(s)
£0.00 10,050
d) Aggregated information N/A (single transaction)
Aggregated volume Price
e) Date of the transaction 2026-02-09
f) Place of the transaction N/A
1. Details of PDMR/person closely associated with them ('PCA')
a) Name Neil Falkingham
b) Position/status PCA of Lynn Baxter (President, Europe)
c) Initial notification/ Initial notification
amendment
2. Details of the issuer, emission allowance market participant, auction
platform, auctioneer or auction monitor
a) Name GSK plc
b) LEI 5493000HZTVUYLO1D793
3. Details of the transaction(s): section to be repeated for (i) each type of
instrument; (ii) each type of transaction; (iii) each date; and (iv) each
place where transaction(s) has been conducted
a) Description of the financial instrument Ordinary shares of 31 ¼ pence each ('Ordinary Shares')
ISIN: GB00BN7SWP63
b) Nature of the transaction The sale of Ordinary Shares to meet tax liabilities on the vesting of awards
granted in 2023 under the Company's Share Value Plan
c) Price(s) and volume(s) Price(s) Volume(s)
£21.9082 4,373
d) Aggregated information N/A (single transaction)
Aggregated volume Price
e) Date of the transaction 2026-02-09
f) Place of the transaction London Stock Exchange (XLON)
About GSK
GSK is a global biopharma company with a purpose to unite science, technology,
and talent to get ahead of disease together. Find out more at www.gsk.com
(http://www.gsk.com/) .
Registered in England & Wales:
No. 3888792
Registered Office:
79 New Oxford Street
London
WC1A 1DG
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
or visit
www.rns.com (http://www.rns.com/)
.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
. END DSHSFDFLFEMSEFE
Copyright 2019 Regulatory News Service, all rights reservedRecent news on GSK
See all newsREG - GSK PLC - Director/PDMR Shareholding
AnnouncementREG - GSK PLC - Transaction in Own Shares
AnnouncementREG - GSK PLC - Linerixibat accepted for priority review in China
AnnouncementREG - GSK PLC - Transaction in Own Shares
AnnouncementREG - GSK PLC - Bepirovirsen accepted for Japan regulatory review
Announcement